Who are Lassogen's investors?

Lassogen's investors include Better Ventures Central Llc, First In Ventures, Playground Global.

How much funding has Lassogen raised?

Lassogen has disclosed $5.1M raised across 1 round.

Where is Lassogen headquartered?

Lassogen is headquartered in San Diego, US.

Lassogen

San Diego, US · Founded 2019 · Delaware corporation · 3 employees on LinkedIn · 3 known investors

Find your way into Lassogen

Paths you didn't know you had: your email and LinkedIn already hold routes to the Lassogen team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Lassogen engineers lasso peptides — structurally unique 3D scaffolds — into therapeutics it calls Lassotides, designed to combine the strengths of antibodies and small molecules. The company develops these therapeutics to treat challenging diseases and disease targets inadequately addressed by existing approaches.

AI & Machine Learning Biotech

Founders & leadership

Mark J Burk Founder, President and CEOExecutive Officer at Genomatica

Investors · 3

Better Ventures Central Llclisted by Better Ventures Central LlcOakland · $500K – $1.5M

How we know: Better Ventures Central Llc's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us

First In Ventureslisted by First In VenturesMiddletown · $50K – $200K

How we know: the VCSheet dataset · Not right? Tell us

Playground GlobalreportedPalo Alto · $1M – $20M

How we know: funding news · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$5.1M disclosed across 1 round · 2020

▶$5.1MraisedSep 2020 · 16 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Mark J BurkExecutive Officer

Offering amount: $5.1M
Amount sold: $5.1M
First sale: Sep 2020
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Lassogen went on to found or lead other companies.

Phyllis WhiteleyChairperson of the BoardFounded NaluBio, Inc.Mark BurkExecutive OfficerFounded Snap Bio

Related companies · 6

RscThe Royal Society of Chemistry is a professional membership organisation that connects the global chemistry community through partnerships, conferences, networks and publications. It sets standards for chemical scientists, promotes open access to scientific knowledge, and advocates for chemistry's role in addressing societal challenges including healthcare, environmental protection, and clean energy.

VersogenVersogen develops anion exchange membrane (AEM) electrolyzers that produce green hydrogen at scale for decarbonizing the energy, chemical, and manufacturing sectors. The company operates in the clean energy and hydrogen technology space.

Saliogen TherapeuticsSalioGen Therapeutics was a genetic medicine company. The company is no longer operating.

SolugenSolugen develops a biomanufacturing platform using fermentation and bioprocessing technology to produce specialty chemicals at scale. The company serves customers in energy, chemicals, and related industries with cost-effective alternatives to traditional petrochemical-based manufacturing.

Solid BiosciencesSolid Biosciences is a precision genetic medicine company developing a pipeline of gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, CPVT, and TNNT2-mediated dilated cardiomyopathy. It also develops genetic regulator libraries and delivery platform technologies intended to improve gene therapy delivery.

SOLA BiosciencesSOLA Biosciences is a preclinical-stage biopharmaceutical company developing gene therapies for neurodegenerative diseases like ALS, Huntington's Disease, and Alzheimer's Disease by targeting misfolded proteins. The company uses its proprietary JUMP70 platform to restore protein homeostasis and deliver disease-modifying treatments.

Companies working in the same space as Lassogen.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase I	2021	$399.6K
National Institutes of Health (NIH)National Institutes of Health	Phase ISTTR	2020	$225K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Lassogen do?: Lassogen engineers lasso peptides — structurally unique 3D scaffolds — into therapeutics it calls Lassotides, designed to combine the strengths of antibodies and small molecules. The company develops these therapeutics to treat challenging diseases and disease targets inadequately addressed by existing approaches.
Who are Lassogen's investors?: Lassogen's investors include Better Ventures Central Llc, First In Ventures, Playground Global.
How much funding has Lassogen raised?: Lassogen has disclosed $5.1M raised across 1 round.
Where is Lassogen headquartered?: Lassogen is headquartered in San Diego, US.